Council of Europe adopts Resolution on Principles of Immunoglobulin Therapies for PIDs
The Council of Europe adopted an important Resolution about Therapies for Primary Immunodeficiencies. Very exciting news that will help our members' advocacy efforts in this year's World Primary Immunodeficiencies Week and beyond!
The Resolution CM/Res(2015)2 on Principles regarding Immunoglobulin Therapies for Immunodeficiency and Other Diseases, adopted on the 15th of April, outlines short but key messages such as the importance of making “available to patients all recognised routes of human normal immunoglobulin administration”, “to take into account that human normal immunoglobulin therapeutic products differ from one another in terms of production processes” and “to adopt a suitable process. This resolution will provide good support to IPOPI's advocacy efforts as well as those of our National Member Organisations.
Jose Drabwell, IPOPI President, stated: “We are delighted that with this Resolution the Council of Europe has formally recognised vital recommendations concerning immunoglobulin therapies and their use in different indications including Primary Immunodeficiencies (PIDs)”. Jose added: “The fact the resolution has come out just in time for the World Primary Immunodeficiency Week (WPIW) to be held from 22 to 29 April 2015 will further raise awareness about the essential nature of immunoglobulin therapies and their importance in the treatment of patients living with primary immunodeficiencies”.
For more details please read IPOPI's press release
The official resolution document can be viewed here
Registration No. 1058005